Skip to main content

Table 2 Anatomical distribution of sarcoidosis lesions on FLT- and FDG-PET (N = 14)

From: FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET

Anatomical site FLT-PET FDG-PET p value Agreement
Lymph nodes     
Thoracic 10/14 (71%) 10/14 (71%) 0.99 0.65 (95% CI 0.21 to 1.0)
Cervical 7/14 (50%) 8/14 (57%) 0.72 0.29 (95% CI − 0.21 to 0.78)
Abdominal/pelvic 1/14 (7.1%) 5/14 (36%) 0.077 0.32 (95% CI − 0.18 to 0.81)
Heart     
Left ventricle 6/14 (43%) 7/14 (50%) 0.72 0.86 (95% CI 0.59 to 1.0)
Right ventricle 2/14 (14%) 4/14 (29%) 0.38 0.59 (95% CI 0.11 to 1.0)
Central nervous system     
Intracranial 1/14 (7.1%) 0/14 (7.1%) 0.33 0.0 (95% CI 0.0 to 0.0)
Spinal/paraspinal 1/14 (7.1%) 1/14 (7.1%) 0.99 1.0 (95% CI 1.0 to 1.0)
Lung parenchyma     
5/14 (36%) 5/14 (36%) 0.99 0.69 (95% CI 0.29 to 1.0)
Salivary glands     
0/14 (0%) 1/14 (7.1%) 0.33  − 0.11 (95% CI − 0.26 to 0.04)
Spleen     
0/14 (0%) 1/14 (7.1%) 0.33 0.0 (–)
Liver     
0/14 (0%) 0/14 (0%)
Bone     
0/14 (0%) 0/14 (0%)
Average number of sites/per subject with active disease     
1.6 (1.0) 1.8 (1.3) 0.75 0.78 (95% 0.45 to 0.93)
  1. FLT-PET = 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography, FDG-PET = 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography
  2. Agreement between categorical and continuous variables was assessed using Cohen’s kappa and the intraclass correlation coefficient, respectively